Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068791 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin-facilitated Treatment for Chronic Pain
A Early Phase 1 study of Fibromyalgia, Primary, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05068791 is a Early Phase 1 study of Fibromyalgia, Primary that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05068791, a Early Phase 1 study of Fibromyalgia, Primary, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.
Conditions Studied
Interventions
- DRUG Psilocybin
- DRUG Dextromethorphan
Study Locations (1)
Alabama
- UAB Beacon Tower - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05068791
The ClinicalTrials.gov registry entry for NCT05068791 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibromyalgia, Primary appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.
NCT05068791 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05068791 about?
NCT05068791 is a clinical study titled "Psilocybin-facilitated Treatment for Chronic Pain". The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and qu...
What is the current status of trial NCT05068791?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05068791 study?
This clinical trial studies the following conditions: Fibromyalgia, Primary.
What interventions are being tested in trial NCT05068791?
The interventions under investigation include: Psilocybin (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT05068791?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05068791 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia, Primary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.